AzurRx BioPharma (AZRX) PT Set at $8.00 by HC Wainwright

AzurRx BioPharma (NASDAQ:AZRX) has been given a $8.00 price target by HC Wainwright in a note issued to investors on Friday. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 139.52% from the stock’s current price.

AzurRx BioPharma (NASDAQ AZRX) traded down $0.07 on Friday, reaching $3.34. The company’s stock had a trading volume of 28,543 shares, compared to its average volume of 64,151. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.

AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.13). equities research analysts forecast that AzurRx BioPharma will post -1.05 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parsons Capital Management Inc. RI grew its holdings in AzurRx BioPharma by 37.2% in the 3rd quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock valued at $1,015,000 after buying an additional 68,920 shares during the period. Ardsley Advisory Partners purchased a new stake in shares of AzurRx BioPharma during the 2nd quarter worth about $141,000. Susquehanna International Group LLP purchased a new stake in shares of AzurRx BioPharma during the 3rd quarter worth about $131,000. Finally, IHT Wealth Management LLC grew its holdings in shares of AzurRx BioPharma by 15.3% during the 2nd quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock worth $486,000 after purchasing an additional 464 shares during the period. Institutional investors own 8.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at

About AzurRx BioPharma

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply